Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Paediatrics
Infant And Child Health
Safety And Efficacy Of Atropine 0.05% Versus 0.01% For Prevention Of Myopic Progression In Indian Children: A Randomized Clinical Trial.

Home
Research Domains
Biomedical And Clinical Sciences
Paediatrics
Infant And Child Health
Safety And Efficacy Of Atropine 0.05% Versus 0.01% For Prevention Of Myopic Progression In Indian Children: A Randomized Clinical Trial.

Related Experiment Video

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

Safety and Efficacy of Atropine 0.05% Versus 0.01% for Prevention of Myopic Progression in Indian Children: A Randomized Clinical Trial.

Siddharam S Janti¹, Kalpana Mali², Eereti Sahithi¹

¹Ophthalmology, All India Institute of Medical Sciences, Bibinagar, Bibinagar, IND.

|June 13, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study found that 0.05% atropine eye drops are more effective than 0.01% atropine and placebo in slowing myopia progression in children. Side effects were mild and well-tolerated, with 0.05% atropine showing the most significant results.

Keywords:

accommodation atropine 0.01%axial length photophobia

More Related Videos

Inducement and Evaluation of a Murine Model of Experimental Myopia

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

Related Experiment Videos

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

Inducement and Evaluation of a Murine Model of Experimental Myopia

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

Area of Science:

Ophthalmology
Pediatric Medicine
Pharmacology

Background:

Myopia, or nearsightedness, is a growing public health concern in children.
Effective interventions are needed to slow the progression of myopia.
Low-dose atropine eye drops have shown promise in managing pediatric myopia.

Purpose of the Study:

To compare the efficacy and safety of 0.01% and 0.05% atropine eye drops versus placebo in controlling myopia progression in children.
To evaluate the impact of different atropine concentrations on refractive error and axial length.
To assess the safety profile and tolerability of low-dose atropine in pediatric myopia management.

Main Methods:

A randomized, interventional study involving 272 children aged 5-16 years with myopia.

progressive myopia

Participants were assigned to receive 0.01% atropine, 0.05% atropine, or placebo eye drops.

Ophthalmic examinations, including cycloplegic refraction and axial length measurements, were conducted over one year.

Main Results:

Both 0.01% and 0.05% atropine significantly slowed myopia progression compared to placebo.
0.05% atropine demonstrated superior efficacy, with greater reductions in refractive progression and axial elongation.
Increased near point of accommodation and pupil size were observed, with more pronounced effects in the 0.05% group; side effects were mild.

Conclusions:

0.05% atropine eye drops are more effective than 0.01% atropine and placebo for managing myopia progression in children.
Low-dose atropine is a safe and well-tolerated treatment option for pediatric myopia.
The findings support the use of 0.05% atropine as a primary intervention for slowing myopia progression in children.